Next Level Private LLC Has $1.55 Million Holdings in Pfizer Inc. (NYSE:PFE)

Next Level Private LLC lifted its holdings in Pfizer Inc. (NYSE:PFE) by 13.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 53,772 shares of the biopharmaceutical company’s stock after purchasing an additional 6,214 shares during the quarter. Next Level Private LLC’s holdings in Pfizer were worth $1,548,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in PFE. Fulton Bank N.A. raised its position in Pfizer by 4.7% during the third quarter. Fulton Bank N.A. now owns 176,239 shares of the biopharmaceutical company’s stock worth $5,846,000 after acquiring an additional 7,991 shares in the last quarter. Portside Wealth Group LLC bought a new position in shares of Pfizer in the second quarter valued at about $2,072,000. Adage Capital Partners GP L.L.C. raised its position in shares of Pfizer by 40.5% in the third quarter. Adage Capital Partners GP L.L.C. now owns 4,739,672 shares of the biopharmaceutical company’s stock valued at $157,215,000 after purchasing an additional 1,365,295 shares during the period. Brookstone Capital Management raised its position in shares of Pfizer by 88.5% in the third quarter. Brookstone Capital Management now owns 452,352 shares of the biopharmaceutical company’s stock valued at $14,109,000 after purchasing an additional 212,369 shares during the period. Finally, ETF Store Inc. raised its position in shares of Pfizer by 12.0% in the third quarter. ETF Store Inc. now owns 6,803 shares of the biopharmaceutical company’s stock valued at $214,000 after purchasing an additional 727 shares during the period. Institutional investors own 68.36% of the company’s stock.

Pfizer Trading Up 0.7 %

Shares of Pfizer stock opened at $27.78 on Thursday. The firm’s 50 day moving average is $27.47 and its 200 day moving average is $29.47. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. Pfizer Inc. has a 1 year low of $25.61 and a 1 year high of $42.22. The firm has a market capitalization of $157.31 billion, a PE ratio of 77.14, a price-to-earnings-growth ratio of 1.24 and a beta of 0.61.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, topping the consensus estimate of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The business had revenue of $14.25 billion for the quarter, compared to the consensus estimate of $14.37 billion. During the same period last year, the company earned $1.14 EPS. The firm’s revenue was down 41.3% compared to the same quarter last year. Equities research analysts forecast that Pfizer Inc. will post 2.22 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. UBS Group decreased their price target on shares of Pfizer from $34.00 to $27.00 and set a “neutral” rating on the stock in a research note on Thursday, December 14th. TD Cowen downgraded shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target on the stock. in a research note on Thursday, January 4th. Barclays decreased their price target on shares of Pfizer from $34.00 to $28.00 and set an “equal weight” rating on the stock in a research note on Thursday, December 14th. Finally, Truist Financial decreased their price target on shares of Pfizer from $42.00 to $36.00 and set a “buy” rating on the stock in a research note on Thursday, December 14th. Twelve analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $36.88.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.